A molecular docking study of phytochemical estrogen mimics from dietary herbal supplements by unknown
Powers and Setzer In Silico Pharmacology  (2015) 3:4 
DOI 10.1186/s40203-015-0008-zORIGINAL RESEARCH Open AccessA molecular docking study of phytochemical
estrogen mimics from dietary herbal supplements
Chelsea N Powers and William N Setzer*Abstract
Purpose: The purpose of this study is to use a molecular docking approach to identify potential estrogen mimics
or anti-estrogens in phytochemicals found in popular dietary herbal supplements.
Methods: In this study, 568 phytochemicals found in 17 of the most popular herbal supplements sold in the United
States were built and docked with two isoforms of the estrogen receptor, ERα and ERβ (a total of 27 different protein
crystal structures).
Results: The docking results revealed six strongly docking compounds in Echinacea, three from milk thistle (Silybum
marianum), three from Gingko biloba, one from Sambucus nigra, none from maca (Lepidium meyenii), five from chaste
tree (Vitex agnus-castus), two from fenugreek (Trigonella foenum-graecum), and two from Rhodiola rosea. Notably,
of the most popular herbal supplements for women, there were numerous compounds that docked strongly with
the estrogen receptor: Licorice (Glycyrrhiza glabra) had a total of 26 compounds strongly docking to the estrogen
receptor, 15 with wild yam (Dioscorea villosa), 11 from black cohosh (Actaea racemosa), eight from muira puama
(Ptychopetalum olacoides or P. uncinatum), eight from red clover (Trifolium pratense), three from damiana (Turnera
aphrodisiaca or T. diffusa), and three from dong quai (Angelica sinensis). Of possible concern were the compounds
from men’s herbal supplements that exhibited strong docking to the estrogen receptor: Gingko biloba had three
compounds, gotu kola (Centella asiatica) had two, muira puama (Ptychopetalum olacoides or P. uncinatum) had eight,
and Tribulus terrestris had six compounds.
Conclusions: This molecular docking study has revealed that almost all popular herbal supplements contain
phytochemical components that may bind to the human estrogen receptor and exhibit selective estrogen receptor
modulation. As such, these herbal supplements may cause unwanted side effects related to estrogenic activity.
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The use of alternative medicines in the United States,
particularly herbal supplements, has dramatically increased
since the beginning of the 21st century (Figure 1). Filling
American minds with promises of enhanced beauty,
sharper senses, and optimum organ functions, herbal
supplements claim to increase, or improve almost all issues
a person could have with their body. Without a doubt it is
appealing to have problems solved by simply swallowing a
pill or drinking a tea, not much effort required, however it
has been widely ignored the consecutive consequences
these supplements can provide (Cupp 1999).* Correspondence: wsetzer@chemistry.uah.edu
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reproduction in any medium, provided the origTwo major factors play a part in the ongoing, unnoticed
herbal supplement crisis: Regulations for herbal supple-
ments and uneducated consumers. Beginning with the first,
the United States does not classify herbal supplements as
drugs, and therefore supplements are not required to
undergo the extensive testing that pharmaceutical drugs do
before put on the market. Courtesy of the “Dietary
Supplement Health and Education Act of 1994”, herbal
supplements are not evaluated by the Food and Drug
Administration (Calixto 2000) making it easy for supple-
ment companies to rapidly introduce new supplements to
consumers, with or without the knowledge of possible
harmful side effects. Unspecified drugs, contaminations,
toxins, and/or heavy metals (Au et al. 2000) can be included
in an herbal supplement, and since companies are nothis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and

















Figure 1 Relationship between herbal supplement purchases in the United States and the year.
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spectrum of harmful compounds could be digested by a
consumer and induce adverse effects. As for the second,
biologically uneducated consumers do not understand or
simply do not consider the concept that plants are not
always beneficial. They believe anything that is natural must
be good for their health and safe to consume (Stonemetz
2008), which is far from the truth. Plants contain hundreds
of phytochemicals, some of which are indeed toxic to
the human body. One class of phytochemicals of major
concern, which is the focus of this study, phytoestrogens,
can interfere and react with the human estrogen receptors,
which regulate neural, skeletal, cardiovascular, and repro-
ductive tissues. This interference, however, is not always ad-
verse. For example, some phytoestrogens can promote
carcinogenic growth, while others can inhibit the growth.
The purpose of this study was to identify potential estro-
gen mimics or anti-estrogens in phytochemicals found in
popular dietary herbal supplements. The data gathered
can only suggest the possibility of a phytochemical to be
an anti-estrogen or a mimic, not confirm its estrogenic
properties. It is our hope that the discoveries made during
this study can help to identify the estrogenic activity of the
phytochemicals examined. This information can then lead
to the health benefits or hazards associated with the
phytochemicals, which in turn could greatly affect the
increasingly popular herbal supplement movement.
Methods
Literature survey
A literature survey on herbal supplements was carried out
to identify the most popular general [Echinacea, milk thistle
(Silybum marianum), Ginkgo biloba, Sambucus nigra, maca
(Lepidium meyenii), chaste tree (Vitex agnus-castus), fenu-
greek (Trigonella foenum-graecum), and Rhodiola rosea],
women’s [damiana leaf (Turnera aphrodisiaca, T. diffusa),muira puama (Ptychopetalum olacoides, P. uncinatum),
black cohosh (Actaea racemosa =Cimifuga racemosa),
licorice root (Glycyrrhiza glabra), wild yam (Dioscorea
villosa), dong quai (Angelica sinensis) and red clover
(Trifolium pretense)], and men’s [Gingko biloba, gotu kola
(Centella asiatica), muira puama (Ptychopetalum olacoides,
P. uncinatum), and Tribulus terrestris] herbal supplements
advertised and used in the United States. A survey of the
literature, including the Dictionary of Natural Products
(2014) and Duke’s Phytochemical Database (1998), was
carried out to determine the phytochemical constituents of
each herb.
Molecular modeling of phytochemicals
Each phytochemical ligand structure (see Figures 2, 3, 4, 5,
6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,
39, 40, 41, 42, and 43) was built using Spartan ’14 for
Windows (2013). For each ligand, a conformational search
and geometry optimization was carried out using the
MMFF force field (Halgren 1996).
Molecular docking
Protein-ligand docking studies were carried out based on
the crystal structures of human estrogen receptor α [ERα:
PDB 1X7E (Manas et al. 2004a), PDB 1X7R (Manas et al.
2004b), and PDB 3ERD (Shiau et al. 1998)] and human
estrogen receptor β [ERβ: PDB 1U3Q, 1U3R, 1U3S
(Malamas et al. 2004), 1U9E, 1X7B, 1X76, 1X78 (Manas
et al. 2004a), and 1X7J (Manas et al. 2004b)]. Prior to
docking all solvent molecules and the co-crystallized
ligands were removed from the structures. Molecular
docking calculations for all compounds with each of the
proteins were undertaken using Molegro Virtual Docker
v. 6.0 (2013). Potential binding sites in the protein struc-



































































































































Figure 2 Alkaloid ligands examined in this work.
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The location of the volume used by the docking search
algorithm was positioned at the center of the cavity and a
sphere (15 Å radius) large enough to encompass the entire
cavity of the binding site of each protein structure was
selected in order to allow each ligand to search. If a co-
crystallized inhibitor or substrate was present in the
structure, then that site was chosen as the binding site. If
no co-crystallized ligand was present, then suitably sized
(>50 Å3) cavities were used as potential binding sites. The
docking searches were constrained to those cavities.
Standard protonation states of the proteins based on neu-
tral pH were used in the docking studies. Each protein
was used as a rigid model structure; no relaxation of the
protein was performed. Assignments of charges on eachprotein were based on standard templates as part of the
Molegro Virtual Docker (2013) program (Thomsen and
Christensen 2006); no other charges were necessary to be
set. Flexible ligand models were used in the docking and
subsequent optimization scheme. As a test of docking ac-
curacy and for docking energy comparison, co-crystallized
ligands were re-docked into the protein structures (see
Table 1). Additionally, as positive controls, the known
estrogenic compounds 17β-estradiol and α-zearalenone
were docked with each protein structure in order to com-
pare docking energies with the herbal phytochemicals.
Different orientations of the ligands were searched and
ranked based on their energy scores. The RMSD threshold
for multiple cluster poses was set at <1.00 Å. The docking










































































Figure 3 Chalcone ligands examined in this work.
Powers and Setzer In Silico Pharmacology  (2015) 3:4 Page 4 of 63simplex evolution population size of 50 and a minimum
of 30 runs for each ligand. Each binding site of oligomeric
structures was searched with each ligand. The lowest-
energy (strongest-docking) poses for each ligand in each
protein target are summarized in Tables 2, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12, 13, 14 and 15.
Results
Alkaloids
The alkaloid ligands examined in this study are shown in
Figure 2. The molecular docking results for the alkaloids
are summarized in Table 2. Of the alkaloids examined in
this study, cis- and trans-clovamide, with docking energies
of −119.8 and −113.6 kJ/mol, respectively, and N-trans-
feruloyltyramine (Edock = −103.1 kJ/mol) were found to
dock well with ERα. Their docking energies were more
exothermic than those of estradiol, −92.0 kJ/mol and the
corresponding co-crystallized ligand genistein, −93.4 kJ/mol,
and the clovamides were more exothermic than zearale-
none (Edock = −104.1 kJ/mol). The co-crystallized ligand,genistein, and the clovamide and feruloylyramine ligands
have similar positions in the binding site (Figure 44). Phe
404, Leu 525, Leu 346, Leu 387, and Leu 391 form a
hydrophobic pocket around the docked alkaloids. Phe
404 exhibited edge-to-face π–π interactions between the
phenyl substituent of Phe with the caffeic or ferulic sub-
stituents of the alkaloids and with the hydroxyphenyl
substituent of genistein. Notable hydrogen bonds in the
lowest-energy docked pose of cis-clovamide were the 3-
OH and 4-OH of the cis-caffeic moiety with the carboxyl-
ate residue of Glu 353 and the 3-OH group with the
guanidine residue of Arg 394 (Figure 45). The docked
trans-clovamide had hydrogen bonds between the 4-OH
of the caffeate with the guanidine of Arg 394 and the
carbonyl group of Leu 387 and the 3-OH group with the
carboxylate of Glu 353. Hydrogen bonds were formed
between the 4-OH group on the ferulyl substituent of
N-trans-feruloyltyramine and carbonyl group of Leu 387,



































































































Figure 4 Coumarin ligands examined in this work.
Powers and Setzer In Silico Pharmacology  (2015) 3:4 Page 5 of 63Similarly, cis-clovamide, trans-clovamide, and N-trans-fer-
uloyltyramine were the alkaloids that docked well with ERβ.
Their docking energies (−124.9, −122.0, and −113.8 kJ/mol,
respectively) were more exothermic than those of estradiol,
−100.0 kJ/mol, zearalenone, −104.9 kJ/mol, and the
corresponding co-crystallized ligand 2-(3-fluoro-4-hydroxy-
phenyl)-7-vinyl-1,3-benzoxazol-5-ol, −107.9 kJ/mol. The
alkaloid and the co-crystallized ligand occupied similar posi-
tions in the binding site, a hydrophobic pocket formed by
Leu 298, Phe 356, Leu 339, and His 475. Phe 356 exhibited
edge-to-face π–π interactions with the caffeic or ferulic
substituents of the docked alkaloid ligands as well as with
the hydroxyphenyl substituent of the co-crystallized ligand.
There were two notable hydrogen bonds formed between
the 4-OH group on the ferulyl substituent of N-trans-feru-
loyltyramine and the guanidine group of Arg 346, and the
carboxylate of Glu 305 (Figure 46). These same two residues
formed hydrogen bonds with the 4-hydroxyphenyl group ofthe co-crystallized ligand. The caffeoyl group of cis-clova-
mide formed hydrogen bonds with Glu 305 and Leu 298.
trans-Clovamide, however, formed hydrogen bonds with
Leu 339, Arg 346, and Glu 305.
Chalcones
The structures of the chalcones are shown in Figure 3,
while the docking energies are summarized in Table 3.
Xanthohumol was the strongest docking chalcone with
ERα. Its docking energy, −116.8 kJ/mol, is more exother-
mic than those of estradiol, −92.0 kJ/mol, zearalenone,
−104.1 kJ/mol, and the corresponding co-crystallized
ligand genistein, −93.4 kJ/mol. The 4-OH group of
xanthohumol forms three hydrogen-bonds with the
protein (the carboxylate of Glu 353, the guanidine of Arg
394, and the carbonyl oxygen of Phe 404). The 4′-OH
group of xanthohumol forms hydrogen-bonds with the






























































































Figure 5 Additional coumarin ligands examined in this work.
Powers and Setzer In Silico Pharmacology  (2015) 3:4 Page 6 of 63521. Kanzonol Y (Edock = −111.2 kJ/mol) and licochalcone
B (Edock = −107.8 kJ/mol) were the only other chalcone
ligands to dock well with ERα.
Of the chalcone ligands examined, kanzonol Y (Edock =
−122.4 kJ/mol), xanthohumol (Edock = −116.8 kJ/mol), and
licoagrochalcone A (Edock =−115.5 kJ/mol), docked best
with ERβ. Their docking energies were decidedly more
exothermic than those of estradiol, zearalenone, and the
corresponding co-crystallized ligand 2-(5-hydroxy-naphtha-
len-1-yl)-1,3-benzooxazol-6-ol (Edock = −109.2 kJ/mol). Ap-
parently, the hydrophobic prenyl groups allow for stronger
docking. Thus, kanzonol Y docked to ERβ much better
than the non-prenylated α,2′,4,4′-tetrahydroxydihydrochal-
cone (Edock = −105.0 kJ/mol). In the lowest-energy docked
pose of kanzonol Y, the 3-prenyl group is sandwiched
between the hydrophobic residues of Phe 356 and Leu 339,while the 5′-prenyl group is sandwiched between Leu 476
and Thr 299 (Figure 47). It has been shown that prenylation
of flavonoids and related compounds does alter the estro-
genic activity and often results in antiestrogenic activity
(Kretzschmar et al. 2010; Simons et al. 2012).
Coumarins
The MolDock docking energies of the coumarins are
summarized in Table 4, and the structures of the coumarins
are shown in Figures 4 and 5. Glabrene and pratenol B
were the strongest docking coumarins with ERα (Edock =
−104.8 kJ/mol), more exothermic than either estradiol
(−92.0 kJ/mol) or genistein (−93.4 kJ/mol), and comparable
to zearalenone (−104.1 kJ/mol). The 7-hydroxychromene
moieties of both glabrene and pratenol B are held in a






































































































































Figure 6 Diterpenoid ligands examined in this work.
Powers and Setzer In Silico Pharmacology  (2015) 3:4 Page 7 of 63and Leu 391. Furthermore, there are edge-to-face π–π
interactions between Phe 404 and the chromene benzene
rings of the ligands, as well as hydrogen bonds between the
7-OH group of the chromene and the guanidine group of
Arg 394 and the carboxylate of Glu 356, analogous to the
co-crystallized ligand genistein. Additionally, one of the
carboxylates of pratenol B forms a hydrogen bond with
imidazole substituent NH group of His 475.
In addition to glabrene (Edock = −114.9 kJ/mol) and pra-
tenol B (Edock = −112.0 kJ/mol), mirificoumestan docked
strongly with ERβ with a docking energy of −113.0 kJ/mol.
These compounds docked more exothermically than
estradiol, zearalenone, or the co-crystallized ligand [5-hy-
droxy-2-(4-hydroxyphenyl)-1-benzofuran-7-yl]acetonitrile
(Edock = −107.7 kJ/mol). Glabrene docked into the hydro-
phobic pocket formed by Leu 298, Leu 339, and Phe 356.Phe 356 exhibited edge-to-face π–π interactions with the
hydroxychromene substituent of glabrene. There was a
hydrogen bond between the imidazole substituent NH
group of His 475 and the 5′-OH group of glabrene, and
three hydrogen bonding interactions were seen between
the 7-OH group of glabrene and the carbonyl group of
Leu 339, the guanidine moiety of Arg 346, and the
carboxylate of Glu 305.
Diterpenoids
The structures for the diterpenoid ligands examined in this
work are shown in Figures 6, 7, 8, and 9, and the docking
energies are listed in Table 5. The strongest docking
diterpenoids with ERα were diosbulbin F, diosbulbin K, and
diosbulbin L (Edock = −111.2, −112.1, and −110.8 kJ/mol,
























































































































Figure 7 Additional diterpenoid ligands examined in this work.
Powers and Setzer In Silico Pharmacology  (2015) 3:4 Page 8 of 63hydrophobic binding pocket with the furan group forming
a hydrogen bond to the guanidine of Arg 394. The methyl
ester of diosbulbin F and the carboxylate of diosbulbin L
also formed hydrogen bonds to the imizadole of His 524.
These three diterpenoids also docked strongly to ERβ. In
addition, diosbulbin F, diosbulbin H, ptycho-6α,7α-diol, and
ptycholide IV all had docking energies more exothermic
(Edock = −114.8, −114.1, −122.9, and −114.7 kJ/mol) than
the co-crystallized ligand, 2-(5-hydroxynaphthalen-1-yl)-1,3-benzooxazol-6-ol (Edock =−111.3 kJ/mol). Ptycho-6α,7α-diol
docked with ERβ with hydrogen bonds between the lactone
carbonyl of the ligand and Arg 346 and the 6-OH group of
the ligand with His 475.
Flavonoids
The structures of the flavonoid ligands examined in this
work are shown in Figures 10, 11, 12, 13, 14, 15, 16, and



























































































































Figure 9 Additional diterpenoid ligands examined in this work.



















































































































Figure 10 Flavonoid ligands examined in this work.
Powers and Setzer In Silico Pharmacology  (2015) 3:4 Page 10 of 63flavonoids, luteolin-8-propenoic acid docked the strongest
to ERα, with a docking energy of −113.127 kJ/mol, more
exothermic than those of estradiol, zearalenone, or genis-
tein. A common docking orientation for phenolic ligands
in ERα is the hydrophobic pocket of Leu 387, Phe 404,
Met 388, and Leu 391, along with edge-to-face π–π inter-
actions with Phe 404, and hydrogen bonds between the
phenolic –OH group and the guanidine group of Arg 394
and the carboxylate of Glu 356. The 7-OH group of the
ligand made an additional hydrogen bond with the
carbonyl oxygen of Gly 521. No other flavonoid ligands
showed notably strong docking with ERα.
Luteolin-8-propenoic acid was also the strongest docking
flavonoid with ERβ (Edock =−123.1 kJ/mol), is far more exo-
thermic than estradiol, zearalenone, and the co-crystallized
ligand, 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol (Edock = −106.2 kJ/mol). As observed in other phen-
olic ligands with ERβ, luteolin-8-propenoic acid occupied
the hydrophobic pocket formed by Leu 298, Leu 339, and
Phe 356; edge-to-face π–π interactions of the phenolic
ligand with Phe 356 and hydrogen boding of the phenolic
–OH group with the carbonyl group of Leu 339, the guan-
idine group of Arg 346, and the carboxylate of Glu 305.
The 7-OH group of the ligand made additional hydrogen
bonds with the carbonyl oxygen of Gly 472 and His 475.
Casticin (Edock = −106.4 kJ/mol), gonzalitosin (Edock =
−106.3 kJ/mol), gossypetin (Edock = −105.7 kJ/mol), larici-
trin (Edock =−107.3 kJ/mol), myricetin (Edock =−106.2 kJ/mol),
quercetin (Edock = −106.0 kJ/mol), santin (Edock =
−108.0 kJ/mol), and tricetin (Edock = −106.2 kJ/mol), all
had more exothermic docking energies than estradiol

















































































































Figure 11 Additional flavonoid ligands examined in this work.
Powers and Setzer In Silico Pharmacology  (2015) 3:4 Page 11 of 63crystallized ligand, 2-(5-hydroxynaphthalen-1-yl)-1,3-ben-
zooxazol-6-ol (Edock = −111.3 kJ/mol).
Isoflavonoids
The docking energies of the isoflavonoids are summa-
rized in Table 7 and the structures are shown in
Figure 18, 19, and 20. Genistein is the quintessential es-
trogenic isoflavonoid, but it is a weaker docking ligand
than estradiol or zearalenone for either ERα or ERβ. The
strongest docking isoflavonoid with ERα was the agly-
cone of licoagroside A (Edock = −100.5 kJ/mol), but this
was weaker than zearalenone. On the other hand, several
isoflavonoid ligands docked to ERβ more strongly than
zearalenone: licoagroside A aglycone (Edock = −107.7 kJ/
mol), 1-methoxyphaseollin (Edock = −110.5 kJ/mol), pra-
tensein (Edock = −106.4 kJ/mol), and 3′,5,7-trihydroxy-5′-methoxyisoflavone (Edock = −107.9 kJ/mol), but none of
these docked more strongly than the synthetic co-
crystallized ligand, 2-(5-hydroxynaphthalen-1-yl)-1,3-
benzooxazol-6-ol (Edock = −111.3 kJ/mol).
Lignans
The structures and the docking energies of the lignans are
shown in Figure 21 and Table 8, respectively. Nortrachelo-
genin and 7′-hydroxymatairesinol were the strongest
docking lignans to ERα (Edock = −112.0 and −112.3 kJ/mol,
respectively). Nortrachelogenin was also the strongest
docking lignan to ERβ (Edock = −125.4 kJ/mol). Sesamin
showed notable selectivity for ERβ over ERα (Edock =
−121.8 and −99.1 kJ/mol, respectively). Nortrachelogenin
occupied the same orientation and hydrogen-bonding













































































































Figure 12 Additional flavonoid ligands examined in this work.
Powers and Setzer In Silico Pharmacology  (2015) 3:4 Page 12 of 63–OH groups hydrogen bonded to argenine in the binding
pocket (Arg 394 in ERα; Arg 346 in ERβ) and the other
phenolic –OH group hydrogen bonded to the histidine
(His 524 in ERα; His 475 in ERβ).
Phenanthrenoids
The docking energies and structures of phenanthrenoids
are shown in Table 9 and Figure 22, respectively. None of
the phenanthrenoids examined in this work showed
docking energies lower than estradiol or zearalenone for
ERα or ERβ.
Miscellaneous phenolics
The docking energies for miscellaneous herbal phenolic
compounds are listed in Table 10, and the structures areshown in Figures 23, 24, and 25. The strongest docking
ligands of the miscellaneous phenolic compounds for ERα
was cimicifugic acid F (Edock = −126.2 kJ/mol), and this
ligand also docked strongly with ERβ (Edock = −125.2 kJ/
mol). Several other phenolic ligands docked with very
exothermic energies to ERβ: the aglycone of agnucastoside
C (Edock = −130.0 kJ/mol), caffeoyl-p-coumaroyl tartaric
acid (Edock = −129.8 kJ/mol), cimiracemate B (Edock =
−127.3 kJ/mol), cimiracemate D (Edock = −128.5 kJ/mol),
and fukinolic acid (Edock = −127.3 kJ/mol).
Analogous to other phenolic compounds (see above),
the cinnamate moiety of the lowest-energy pose of
cimicifugic acid F in ERα shows edge-to-face π–π inter-
actions with Phe 404, and hydrogen bonding between








































































































Figure 13 Additional flavonoid ligands examined in this work.
Powers and Setzer In Silico Pharmacology  (2015) 3:4 Page 13 of 63Additionally, the 3-carboxylate group of the ligand is
hydrogen-bonded to His 524, and the phenolic group fits
into a hydrophobic pocket formed by Met 388, Met 421,
and Ile 424.
The lowest-energy docked pose of the aglycone of
agnucastoside C with ERβ, as with other phenolic com-
pounds (see above), has the p-coumarate phenolic –OH
group hydrogen bonded to the carbonyl group of Leu
339 and the guanidine group of Arg 346, and edge-to-
face π–π interactions of the phenolic ligand with Phe
356. The cyclic hemiacetal group is hydrogen bonded to
His 475.Sesquiterpenoids
Of the sesquiterpenoids, only cinnamoylechinadiol gave a
notable docking energy (−120.8 kJ/mol) with ERβ (Figure 26,
Table 11).
Steroids
The steroidal ligands examined in this study are shown in
Figures 27, 28, 29, 30, 31, 32, 33, and 34, and their docking
energies are listed in Table 12. Several pregnane steroids
exhibited docking energies less than the co-crystallized
ligand 2-(5-hydroxynaphthalen-1-yl)-1,3-benzooxazol-6-ol






































































































Figure 14 Additional flavonoid ligands examined in this work.
Powers and Setzer In Silico Pharmacology  (2015) 3:4 Page 14 of 63en-20-one (Edock =−116.6 kJ/mol), 3,16-dihydroxypregn-5-
en-20-one (Edock =−116.6 kJ/mol), 3,21-dihydroxypregna-
5,16-dien-20-one (Edock = −121.4 kJ/mol), and pregnadieno-
lone (Edock = −115.4 kJ/mol). The lowest-energy docked
poses of the pregnane ligands show them all to adopt the
same orientation (Figure 48) with key hydrogen-bonding
interactions of the 3-OH group of the steroids with the guan-
idine of Arg 346 and the amide carbonyl of Leu 339, and the
20-ketone group of the ligand with the imidazole N-H of His
475. Two ligands, 3,16-dihydroxypregn-5-en-20-one and
3,21-dihydroxypregna-5,16-dien-20-one, showed selectivity
for ERβ over ERα (24.8 and 18.4 kJ/mol, respectively).
Stilbenoids
Structures and docking energies for the stilbenoid ligands
are shown in Figures 35 and 36, and Table 13, respectively.Several stilbenoid ligands showed notably strong docking
energies; lower than estradiol, zearalenone, or the
respective co-crystallized ligands: 3-acetoxy-4′,5-dihy-
droxy-3′-prenyldihydrostilbene (Edock to ERα = −119.0 kJ/
mol), licoagrodione (Edock to ERβ = −116.9 kJ/mol),
3,3′,4,5′-tetrahydroxy-4′,5-diprenylbibenzyl (Edock to ERβ
= −117.1 kJ/mol), 3,3′,4,5′-tetrahydroxy-5-prenylbibenzyl
(Edock to ERβ = −115.0 kJ/mol), and uralstilbene (Edock to
ERβ = −122.1 kJ/mol). Prenylation of stilbenoids seems to
improve docking energies by about 20 kJ/mol.Triterpenoids
Docking energies are presented in Table 14 and structures
of triterpenoid ligands are illustrated in Figures 37, 38, 39,



























































































Figure 15 Additional flavonoid ligands examined in this work.
Powers and Setzer In Silico Pharmacology  (2015) 3:4 Page 15 of 63triterpenoid ligands that showed good docking with either
ERα or ERβ.
Miscellaneous phytochemicals
Several miscellaneous phytochemicals found in herbal
supplements were included in this study (Table 15,
Figures 42 and 43). Of these ligands, orobanchyl acetate
gave excellent docking energies for both ERα and ERβ
(Edock = −111.3 and −122.8 kJ/mol, respectively).
Discussion
Angelica sinensis
Dong quai (Angelica sinensis root) has been used in
Chinese traditional medicine for thousands of years for
various female health conditions (e.g., dysmenorrhea, pel-
vic pain, symptoms of menopause) (Chye 2006; Al-Bareeqet al. 2010; Fang et al. 2012). In spite of its history, dong
quai provided no clinical relief of menopausal symptoms
(Hirata et al. 1997). In fact, dong quai has been shown to
stimulate the growth of MCF-7 (ER+ human mammary
carcinoma) cells (Lau et al. 2005), but does not bind either
ERα or ERβ (Liu et al. 2001). The plant contains several
miscellaneous phytochemicals, only two of which have
notable docking energies, 10-angeloylbutylphthalide
(−107.1 kJ/mol with ERβ) and angeliferulate (−110.7 and
−121.5 kJ/mol with ERα and ERβ, respectively).
Centella asiatica
Centella asiatica (gotu kola) has been used in Ayurvedic
traditional medicine for cognitive enhancement (Rao et al.
2005), to alleviate symptoms of anxiety and promote relax-














































































































Figure 16 Additional flavonoid ligands examined in this work.
Powers and Setzer In Silico Pharmacology  (2015) 3:4 Page 16 of 63ache, asthma, ulcers, and wound healing (Kumar and
Gupta 2002). Animal studies have revealed cognitive
enhancement (Kumar and Gupta 2002; Rao et al. 2005),
neuroprotective (Subathra et al. 2005), and anxiolytic
(Wijeweera et al. 2006) effects. To our knowledge, there
have been no reports on the estrogenic activity of C.
asiatica.
The plant contains the flavonoids castillicetin, castilliferol,
kaempferol, and quercetin; the triterpenoids 2,3,20,23-tetra-
hydroxy-28-ursanoic acid, 2,3,23-trihydroxy-20-ursen-28-
oic acid, 2,3-dihydroxy-5-(hydroxymethyl)-24-norolean-12-
en-28-oic acid, 3,6,23-trihydroxy-12-ursen-28-oic acid, 6β-
hydroxymaslinic acid, asiatic acid, asiaticoside G, betulafo-
lienetriol, centellasapogenol A, centelloside A, corosolic
acid, isothankunic acid, madasiatic acid, madecassic acid,quasipanaxadiol, terminolic acid, uncargenin C and zemo-
side A; the steroid campesterol, and the miscellaneous
compounds asiaticin, homosilphiperfoloic acid, and irbic
acid. Both quercetin and asiaticin had notable exothermic
docking energies with ERβ (−106.0 and −109.0 kJ/mol,
respectively). Quercetin has shown preferential binding to
ERβ (Kuiper et al. 1998).
Cimicifuga racemosa (syn. Actaea racemosa)
Although black cohosh extracts have demonstrated
clinical efficacy against some symptoms of menopause
(Lieberman 1998; McKenna et al. 2001; Liske et al. 2002;
Pockaj et al. 2004; Wuttke et al. 2006), several studies have
demonstrated little or no estrogenic activity (Liu et al.



























































































Figure 17 Additional flavonoid ligands examined in this work.
Powers and Setzer In Silico Pharmacology  (2015) 3:4 Page 17 of 63The efficacy of C. racemosa extracts on post-menopausal
symptoms has been attributed to partial agonism of the
serotonin receptor (Burdette et al. 2003) and the μ-opiate
receptor (Rhyu et al. 2006).
C. racemosa extracts have revealed several triterpenoids
(Shao et al. 2000), phenylpropanoids (Chen et al. 2002) and
caffeic acid derivatives (Li et al. 2003). Very few of the C.
racemosa triterpenoids showed negative docking energies
and are, therefore, unlikely estrogen receptor binding
agents. Several C. racemosa phenolic compounds did show
remarkable docking affinities for both ERα and ERβ:
cimicifugic acid A, cimicifugic acid B, cimicifugic acid G,
cimiciphenol, cimiciphenone, cimiracemate A, cimirace-
mate B, cimiracemate C, cimiracemate D, and fukinolic
acid. It is likely that any estrogenic activity of C. racemosa
extract (Seidlová-Wuttke et al. 2003a) is due to the pres-
ence of phenolic components rather than triterpenoids.
Dioscorea villosa
The rhizomes of wild yam, Dioscorea villosa, have been
used to treat symptoms associated with menopause and
premenstrual syndrome (PMS) as well as to relieve labor
pains and sooth dysmenorrhea (Dutta 2015). The genus
contains numerous steroidal glycosides (Sautour et al. 2006;
Sautour et al. 2007; Ali et al. 2013). In this work, we have
carried out in-silico screening of phytochemicals from thegenus Dioscorea (Dictionary of Natural Products 2014). Of
these, the diosbulbins D, F, H, J, K, and L (diterpenoids
from D. bulbifera (Komori 1997; Liu et al. 2010) gave
remarkable docking energies with both ERα and ERβ while
the pregnane steroids 3,16-dihydroxypregn-5-en-20-one,
3,21-dihydroxypregna-5,16-dien-20-one, ergost-5-ene-3,26-
diol, and pregnadienolone, showed selective docking with
ERβ. Interestingly, neither furostane nor the spirostane
steroids, common in Dioscorea spp. docked well with the
estrogen receptors. It is worth noting that clinical studies
have shown D. villosa to have little effect on menopausal
symptoms (Komesaroff et al. 2001).
Echinacea spp.
Echinacea (E. angustifolia, E. pallida, and E. purpurea) is
one of the most popular herbal supplements sold in the
United States and has been used as a treatment for the
common cold, coughs, bronchitis, upper respiratory infec-
tions, and inflammatory conditions (Percival 2000). Recent
studies have demonstrated Echinacea to exhibit immune-
system-stimulating activity (Block and Mead 2003).
Phytochemicals that have been isolated from Echinacea
spp. include chicoric acid and monomethyl and dimethyl
ethers, trichocarpinine, cinnamoylechinadiol, cinnamoyle-
chinaxanthol, cinnamoylepoxyechinadiol, cinnamoyldihy-




































































































Figure 18 Isoflavonoid ligands examined in this work.
Powers and Setzer In Silico Pharmacology  (2015) 3:4 Page 18 of 63acid, burkinabin A, burkinabin B, kaempferol, luteolin,
and quercetin. Although Echinacea has not shown estro-
genic activity (Zava et al. 1998), six phytochemicals were
identified in this docking study that showed strong dock-
ing to the estrogen receptor: the flavonoid quercetin; the
phenolic compounds caffeoyl-p-coumaroyltartaric acid,
caftaric acid, and chicoric acid; and the sesquiterpenoids
cinnamoylechinadiol and cinnamoylepoxyechinadiol.
Gingko biloba
G. biloba is commonly used as a supplement to improve
cognitive abilities (Kennedy et al. 2000), and for women
specifically, it has been used to treat some of the side ef-
fects accompanying menopause (Oh and Chung 2004).The extracts of G. biloba have previously been shown to
exhibit feeble estrogenic effects, and act as selective estro-
gen receptor modulators (SERMs) with the α and β estro-
gen receptors (Oh and Chung 2006). Phytochemical
analyses have revealed G. biloba extracts to contain the
flavonoids (2R,3S,4S)-3,3′,4,4′,5,5′,7-heptahydroxyflavan,
8-(5-carboxy-2-methoxyphenyl)-5,7-dihydroxy-4′-meth-
oxyflavone, acacetin, amentoflavone, apigenin, bilobetin,
5′-methoxybilobetin, epigallocatechin, ginkgetin, isogink-
getin, kaempferol, luteolin, quercetin, sciadopitysin, and
tricetin, as well as the lignan sesamin, the sesquiterpenoids
bilobanol, and the steroid globosterol. Of these, quercetin,
tricetin, and sesamin gave large negative docking energies.































































































Figure 19 Additional isoflavonoid ligands examined in this work.
Powers and Setzer In Silico Pharmacology  (2015) 3:4 Page 19 of 63Glycyrrhiza glabra
The phytochemistry of Glycyrrhiza glabra has been well
studied and numerous compounds have been isolated
and identified, including aurones (licoagroaurone and
licoagrone), chalcones (1,2-dihydroparatocarpin A, 2,4,4′-
trihydroxychalcone, 4-hydroxychalcone, cordifolin, isoli-
quiriteginin, licoagrochalcones A-D, licochalcones A and
B, α,2′,4,4′-tetrahydroxydihydrochalcone, and kanzonol
Y), coumarins (2′-O-methylglabridin, 3,4-didehydroglab-
ridin, 3′-hydroxy-4′-methoxyglabridin, 4′-O-methylgrab-
ridin, 4′-O-methylkanzonol W, bergapten, gancaonin F,
glabrene, glabrocoumarin, glycycoumarin, glyinflanin H,
hispaglabridin A, hispaglabridin B, isoglycycoumarin,
isoglycyrol, kanzonol U, kanzonol V, kanzonol W,
and licocoumarin A), flavonoids (3-hydroxyglabrol,6-prenyleriodictyol, 6-prenylpinocembrin, folerogenin,
glabranin, glabrol, isolicoflavonol, isoschaftoside, isovio-
lanthin, kaempferol, kumatakenin, licoagrodin, licoflava-
none, naringenin, norwogonin, pinocembrin, quercetin,




genistein, glabraisoflavanone A, glabraisoflavanone B, glab-
roisoflavanone A, glabridin, glabroisoflavanone B, glabrone,
glyasperin B, glyasperin K, glyzaglabrin, glyzarin, isoder-
rone, isoglabrone, isomucronulatol, kanzonol R, kanzonol
T, kanzonol X, licoagroside A, licoricidin, lupiwighteone,
phaseollinisoflavan, prunetin, shinpterocarpin, tetrapterol




























Figure 20 Additional isoflavonoid ligands examined in this work.





nyldihydrostilbene, licoagrodione, and uralstilbene), and
triterpenoids (11-deoxoglycyrrhetic acid, 18α-glycyrrhetic
acid, 18α-hydroxyglycyrrhetic acid, 21-hydroxyisoglabrolide,
24-hydroxyglycyrrhetic acid, 24-hydroxyliquiritic acid, 28-
hydroxyglycyrrhetic acid, 3,24-dihydroxy-11,13(18)-oleana-
dien-30-oic acid methyl ester, 3,24-dihydroxy-9(11),12-
oleanadien-30-oic acid, 9(11)-dehydroglycyrrhetic acid, β-
amyrin, betulinic acid, desoxoglabrolide, glabric acid, glab-
rolide, glycyrrhetic acid, glycyrrhetol, isoglabrolide, lanosta-
5,24-dien-3-ol, liquiridiolic acid, liquiritic acid, and liquoric
acid).
Licorice (Glycyrrhiza glabra) root has been used for
thousands of years by different cultures and for a variety
of reasons (Fenwick et al. 1990). Although licorice root
has been suggested as a treatment for symptoms of meno-
pause (Ojeda 2003), G. glabra root extracts have been
shown to be inactive in terms of ERα or ERβ binding
(Liu et al. 2001). Nevertheless, however, fractionation of
G. glabra extracts has revealed several ER-modulating
components (Khalaf et al. 2010; Simons et al. 2011). Glab-
rene binds to human ER and shows estrogenic activity
(Tamir et al. 2001; Simons et al. 2011). Our in-silico dock-
ing study shows glabrene to be a strongly docking ligand
to both ERα and ERβ (−104.8 and −114.9 kJ/mol, respect-
ively). Glabridin, on the other hand, displayed ERα-
selective antagonism (Simons et al. 2011), in contrast to
the docking results that showed glabridin to have ERβdocking selectivity (−15.8 and −92.9 kJ/mol, respectively).
The chalcones isoliquiritigenin (Tamir et al. 2001; Maggiolini
et al. 2002) and licochalcone A (Rafi et al. 2000), the fla-
vonoid quercetin (Kuiper et al. 1998), and the isoflavonoid
genistein (Ososki and Kennelly 2003) also bind to human
ERα and show estrogenic activity. These ligands all show
negative docking energies with ERα (range from −93.2 to
−99.9 kJ/mol) and ERβ (−98.9 to −107.8 kJ/mol).Lepidium meyenii
Maca (Lepidium meyenii) is native to the central Andes
of Peru (3500–4500 m asl) (Wang et al. 2007). The root
has been used by native Amerindians to improve fertility,
as an aphrodisiac for both men and women. Maca was
found to increase sperm counts and gonadal mass in a
rat model (Chung et al. 2005), to improve copulatory
performance of male mice and rats (Zheng et al. 2000;
Cicero et al. 2001), and to increase litter size (Ruiz-Luna
et al. 2005) and pregnancy rates in female mice (Kuo
et al. 2003). In adult human males, maca treatment led
to increased semen volume and sperm count (Gonzales
et al. 2001) and increased sexual desire (Gonzales et al.
2002; Stone et al. 2009). In addition, maca reduced sexual
dysfunction in postmenopausal women (Brooks et al.
2008) and inhibited estrogen-deficient osteoporosis in
ovariectomized rats (Zhang et al. 2006), but maca
extracts have not shown estrogenic activity (Brooks et al.
2008). None of the L. meyenii phytochemicals investi-
gated in this in-silico study showed remarkable docking







































































































Figure 21 Lignan ligands examined in this work.
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Muira puama (bark and root extracts of P. olacoides or P.
uncinatum) has been used in Amazonian Brazil during
highly stressful periods, to treat CNS-related ailments,
neuromuscular problems, “nervous weakness”, sexual de-
bility, frigidity, impotence, and rheumatism (Schultes and
Raffauf 1990; Siqueira et al. 1998; Duke et al. 2009). Con-
sistent with these traditional uses, P. olacoides ethanol
root extract has shown memory retrieval improvement in
young and aging mice (da Silva et al. 2004), in-vitro acetyl-
choline esterase inhibitory activity (Siqueira et al. 2003),
and prevention of stress-induced hypothalamic-pituitary-
adrenal hyperactivity (Piato et al. 2008). In addition, Muira
puama formulations have demonstrated efficacy in treat-
ing male erectile dysfunction and low libido (Waynberg1994) and low sex drive in women (Waynberg and Brewer
2000). A number of clerodane diterpenoids have been
isolated from P. olacoides bark (Tang et al. 2008; Tang
et al. 2009; Tang et al. 2011). Several of these have given
excellent docking energies with the estrogen receptor, but
two in particular, ptycho-6α,7α-diol and ptycholide IV had
remarkable docking to ERβ (−122.9 and −114.7 kJ/mol,
respectively). To our knowledge, the estrogenic effects of
Muira puama have not been investigated.
Rhodiola rosea
R. rosea is reputed to strengthen the nervous system, fight
depression, enhance memory, and improve energy levels
(Brown et al. 2002), which has been attributed to adapto-












































































Figure 22 Phenanthrenoid ligands examined in this work.
Powers and Setzer In Silico Pharmacology  (2015) 3:4 Page 22 of 63et al. 2000). The flavonoids gossypetin, herbacetin, and
rhodiolin, and the lignan (+)-lariciresinol, have been
identified in R. rosea. Lariciresinol showed strong docking
to both ERα and ERβ. There are conflicting reports on the
potential estrogenic effects of R. rosea, however (Eagon
et al. 2004; Kim et al. 2005).
Sambucus nigra
The bark, leaves, flowers, fruit, and root extracts of black
elderberry (Sambucus nigra) have been used traditionally
to treat respiratory ailments such as bronchitis, cough, in-
fluenza, and upper respiratory infections (Zakay-Rones
et al. 1995; Krawitz et al. 2011). Compounds identified in
S. nigra extracts include α-amyrin, β-amyrin, α-amyrone,
betulin, campesterol, cycloartenol, lupeol, oleanolic acid,
quercetin, ursolic acid, and dihydrodehydrodiconiferylalcohol (9-acetate). Of these, only the flavonoid quercetin
showed good docking to the estrogen receptor. To our
knowledge, there are no reports on the estrogenic activity
of S. nigra extracts.
Silybum marianum
Milk thistle, Silybum marianum, extracts (silymarin) have
been used for centuries to treat liver diseases (Flora et al.
1998). Silymarin contains the flavonoids apigenin, chrysoer-
iol, cisilandrin, eriodictyol, isocisilandrin, isosilandrin A, iso-
silandrin B, isosilybin A, isosilybin B, isosilybin C, isosilybin
D, isosilychristin, kaempferol, naringenin, neosilyhermin A,
neosilyhermin B, quercetin, silandrin A, silandrin B, silya-
mandin, silybin A, silybin B 2,3-dehydrosilybin, silychristin,
2,3-dehydrosilychristin, silychristin B, silydianin, silyhermin,



































































































Figure 23 Miscellaneous phenolic compounds examined in this work.
Powers and Setzer In Silico Pharmacology  (2015) 3:4 Page 23 of 63alcohol; the steroids 24-methylenelanost-8-ene-3,25,28-triol
and marianine; and the triterpenoids silymin A and silymin
B. Silybin B (also called silibinin) has been shown to select-
ively bind to the ERβ receptor rather than ERα (Seidlová-
Wuttke et al. 2003b) and previous docking studies have
shown selective docking to ERβ over ERα (El-Shitany et al.
2010). In contrast, our current docking study revealed that
neither silybin A nor silybin B gave negative docking ener-
gies with either ERα or ERα. Quercetin and taxifolin, on
the other hand, gave docking energies comparable to zeara-
lenone with ERβ (−106.0, −104.6, and −104.5 kJ/mol, re-
spectively), and these flavonoids have also shown estrogenic
activity (Plíšková et al. 2005). Silymarin modulation of ERβ
may be responsible for the estrogenic effects of the extract
(Seidlová-Wuttke et al. 2003b; Plíšková et al. 2005; El-
Shitany et al. 2010).Tribulus terrestris
Tribulus terrestris has been used to contribute to physical
and sexual strength (De Combarieu et al. 2003; Neychev
and Mitev 2005). The plant is rich in steroidal glycosides
(Wu et al. 1996; Yan et al. 1996; De Combarieu et al. 2003;
Dinchev et al. 2008) and T. terrestris extracts have shown
androgenic effects in animal models (Gauthaman et al.
2002; Gauthaman and Ganesan 2008), but had no influ-
ence on androgen production (Neychev and Mitev 2005)
or gains in strength or muscle mass (Rogerson et al. 2007)
in young men. To our knowledge, there have been no
reports on the estrogenic effects of T. terrestris.
In addition to steroids, several alkaloids (N-trans-feru-
loyltyramine, perlolyrine, terresoxazine, terrestriamide,
tribulusamide A and tribulusamide B) and flavonoids








































































































Figure 24 Additional miscellaneous phenolic compounds examined in this work.
Powers and Setzer In Silico Pharmacology  (2015) 3:4 Page 24 of 63found in T. terrestris. In-silico molecular docking has
shown that N-trans-feruloyltyramine docks strongly to
both ERα and ERβ, perlolyrine docks strongly to ERβ,
terrestribisamide docks strongly to ERα, quercetin docks
strongly to ERβ, and the steroid 2,3-dihydroxypregn-16-
en-20-one docks strongly to both ERα and ERβ.
Trifolium pratense
The alkaloids cis- and trans-clovamide, several coumarins,
flavonoids, and isoflavonoids have been identified in red
clover (Trifolium pratense). Although there have been no
ethnobotanical reports to support it, the presence of
isoflavones has led to suggest that red clover may serve as
a phytochemical alternative to post-menopausal hormonereplacement therapy (Coon et al. 2007). Red clover extract
has been shown to exhibit weakly estrogenic effects in a
rat model (Burdette et al. 2002) and does show in-vitro
ERα and ERβ binding ability (Dornstauder et al. 2001;
Beck et al. 2003; Overk et al. 2005). The clinical effective-
ness of red clover has not, however, been demonstrated
(Fugh-Berman and Kronenberg 2001; Booth et al. 2006).
Biochanin A, daidzein, formononetin, and genistein
have been identified as T. pratense isoflavonoids with ERα
and ERβ binding activity (Beck et al. 2003; Pfitscher et al.
2008) and these compounds did show a binding prefer-
ence for ERβ. Molecular docking of these ligands also
showed preference for ERβ. They were not, however, the



































































































Figure 26 Sesquiterpenoid ligands examined in this work.


































































Figure 27 Steroid ligands examined in this work.
Powers and Setzer In Silico Pharmacology  (2015) 3:4 Page 26 of 63alkaloids cis- and trans-clovamide, and the coumarin
pratenol B showed good docking to both ERα and ERβ. Of
the T. pratense isoflavonoids, calycosin and pseudobapti-
genin had more exothermic docking energies to ERβ than
did biochanin A, daidzein, formononetin, or genistein.
Trigonella foenum-graecum
Fenugreek (Trigonella foenum-graecum) is used as an antidi-
abetic (Abdel-Barry et al. 1997) and for lowering blood lipid
and cholesterol levels (Prasanna 2000). Phytochemicals iden-
tified in T. foenum-graecum include the alkaloid gentianine;
the coumarins 7-acetoxy-4-methylcoumarin, trigocoumarin,
and trigoforin; the flavonoids 2″-O-p-coumaroylvitexin,2″-O-p-coumaroylorientin, 6,8-digalactosylapigenin, 8-
galactopyranosyl-6-quinovopyranosylapigenin, 8-β-D-
galactopyranosyl-6-β-D-xylopyranosylapigenin, isoor-
ientin, isovitexin, kaempferol, luteolin, neocorymboside,
orientin, quercetin, trigraecum, vicenin 1, vicenin 2, and
vicenin 3; the isoflavonoid 3′,5,7-trihydroxy-5′-methox-
yisoflavone; p-coumaric acid; and the steroids 25R-
spirosta-3,5-diene (= Δ3,5-deoxyneotigogenin), diosgenin,
furostane-2,3,22,26-tetrol (= trigoneoside aglycone), gito-
genin, neotigogenin, tigogenin, and yamogenin. Quercetin
and 3′,5,7-trihydroxy-5′-methoxyisoflavone were the stron-
gest docking ligands for ERβ. Fenugreek seed extract has





































































Figure 28 Additional steroid ligands examined in this work.
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Damiana leaf has been used in traditional medicine in
Neotropical cultures as a stimulant and aphrodisiac
(Morton 1981), and the herb is marketed as a sexual
enhancer for men and women. Extracts of T. aphrodi-
siaca have shown aphrodisiac activity in mouse
(Helmrick and Reiser 2000; Kumar et al. 2009) and rat
(Estrada-Reyes et al. 2009; Estrada-Reyes et al. 2013)
models, as well as anxiolytic activity in mice (Kumar and
Sharma 2005). Phytochemical investigations have re-
vealed damiana to be rich in flavonoids, including acace-
tin, apigenin, gonzalitosin, laricitrin, luteolin-8-propenoic
acid, orientin, orientin-3″-ketone, pinocembrin, andsyringetin (Piacente et al. 2002; Zhao et al. 2007). The
extract has shown anti-aromatase (due primarily to
acacetin and pinocembrin) and estrogenic activity (due
primarily to apigenin, Z-echinacin, and pinocembrin)
(Zhao et al. 2008). In contrast to these experimental
results, molecular docking revealed the strongest
docking Turnera compound to be luteolin-8-propenoic
acid (−113.1, −123.1 kJ/mol for ERα and ERβ, respect-
ively) but this compound was inactive in the aromatase
and estrogen assays. In contrast, pinocembrin, which
was active in both experimental assays, had ERα and





































































Figure 29 Additional steroid ligands examined in this work.
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Vitex agnus-castus, “chaste tree”, has been used as a
tonic for female reproductive disorders, including men-
strual disorders (amenorrhea, dysmenorrhea), premen-
strual syndrome (PMS, corpus luteum insufficiency,
hyperprolactinemia, infertility, menopause, and disrupted
lactation (Daniele et al. 2005; van Die et al. 2013). V.
agnus-castus extracts contain several flavonoids (casticin,
isoorientin, 6″-caffeoylisoorientin, 6″-caffeoylisoorien-
tin-4″-methyl ether, isovitexin, luteolin, orientin, santin,
5-O-demethyltangeretin, and vitexin), diterpenoids (8,
14-labdadiene-6,7,13-triol-6,7-diacetate, viteagnuside A,viteagnusin A, viteagnusin B, viteagnusin D, viteagnusin
E, viteagnusin F, viteagnusin G, viteagnusin H, viteagnu-
sin I, viteagnusin J, and vitexlactam A), the isoflavonoid
vitexcarpan, and the phenolic compounds agnucastoside
C and agnuside. Based upon docking energies with ERβ,
casticin, santin, vitexcarpan, and the aglycones of agnu-
castoside C and agnuside, could be expected to exhibit
ER modulation. Indeed, V. agnus-castus extracts have
been shown to bind to ERα (Liu et al. 2001) and ERβ
(Jarry et al. 2003). It has been suggested that V. agnus-
castus is a source of 3-ketosteroids with progesterone-













































































Figure 30 Additional steroid ligands examined in this work.










































































Figure 31 Additional steroid ligands examined in this work.


































































Figure 32 Additional steroid ligands examined in this work.















































































Figure 33 Additional steroid ligands examined in this work.





































































Figure 34 Additional steroid ligands examined in this work.







































































Figure 35 Stilbenoid ligands examined in this work.

































Figure 36 Additional stilbenoid ligands examined in this work.
































































































































Figure 37 Triterpenoid ligands examined in this work.








































































































Figure 38 Additional triterpenoid ligands examined in this work.






















































































































Figure 39 Additional triterpenoid ligands examined in this work.














































































































Figure 40 Additional triterpenoid ligands examined in this work.
























































































Figure 41 Additional triterpenoid ligands examined in this work.














































































Figure 42 Miscellaneous phytochemical ligands examined in this work.


































Figure 43 Additional miscellaneous phytochemical ligands examined in this work.
Table 1 MolDock docking energies of co-crystallized ligands and root-mean-squared deviations between the
co-crystallized ligand and the re-docked poses of the co-crystallized ligand with human estrogen receptors α and β
Protein PDB code Co-crystallized ligand Edock (kJ/mol) RMSD (Å)
ERα 1X7E [5-hydroxy-2-(4-hydroxyphenyl)-1-benzofuran-7-yx]acetonitrile −100.9 0.46
1X7R genistein −95.3 0.44
3ERD diethylstilbestrol −97.0 0.75
ERβ 1U3Q 4-(6-hydroxybenzo[d]isoxazol-3-yl)benzene-1,3-diol −98.9 1.40
1U3R 2-(5-hydroxynaphthalen-1-yl)-1,3-benzooxazol-6-ol −111.3 0.36
1U3S 3-(6-hydroxynaphthalen-2-yl)-benzo[d]isoxazol-6-ol −107.7 0.35
1U9E 2-(4-hydroxyphenyl)benzofuran-5-ol −90.4 0.62
1X7B 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol −107.9 0.46
1X7J genistein −99.9 0.66
1X76 5-hydroxy-2-(4-hydroxyphenyl)-1-benzofuran-7-carbonitrile −101.3 0.42
1X78 [5-hydroxy-2-(4-hydroxyphenyl)-1-benzofuran-7-yl]carbonitrile −107.7 0.40
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Table 2 MolDock molecular docking energies (kJ/mol) for alkaloids with human estrogen receptors α and β
Compound Plant Source ERα ERβ
cimitrypazepine Cimicifuga racemosa −87.6 −75.5
cis-clovamide Trifolium pratense −119.8 −124.9
trans-clovamide Trifolium pratense −113.6 −122.0
dihydrodioscorine Dioscorea spp. −60.2 −64.9
dioscoretine Dioscorea spp. −81.8 −80.9
dioscorine Dioscorea spp. −62.1 −68.1
dopargine Cimicifuga racemosa −97.9 −100.6
dumetorine Dioscorea spp. −77.0 −82.3
N-trans-feruloyltyramine Tribulus terrestris −103.1 −113.8
gentianine Trigonella foenum-graecum −67.2 −64.9
harman Tribulus terrestris −74.9 −67.4
harmine Tribulus terrestris −68.8 −78.0
harmol Tribulus terrestris −85.8 −75.5
lepidiline A Lepidium meyenii −91.2 −96.9
macaridine Lepidium meyenii −78.0 −78.2
perlolyrine Tribulus terrestris −93.4 −104.6
terresoxazine Tribulus terrestris −66.3 −74.7
terrestribisamide Tribulus terrestris −102.1 −101.2
1,2,3,4-tetrahydro-6-hydroxy-2-methyl-β-carboline Cimicifuga racemosa −73.5 −78.2
Tribulusamide A Tribulus terrestris −48.7 no dock
Tribulusamide B Tribulus terrestris no dock no dock
Table 3 MolDock molecular docking energies (kJ/mol) for chalcones with human estrogen receptors α and β
Compound Plant Source ERα ERβ
cordifolin Glycyrrhiza glabra −102.2 −110.2
1,2-dihydroparatocarpin A Glycyrrhiza glabra no dock −11.2
4-hydroxychalcone Glycyrrhiza glabra −88.4 −94.5
isoliquiritigenin Glycyrrhiza glabra −99.9 −102.6
kanzonol Y Glycyrrhiza glabra −111.2 −122.4
licoagrochalcone A Glycyrrhiza glabra −102.4 −115.5
licoagrochalcone B Glycyrrhiza glabra −55.8 −112.0
licoagrochalcone C Glycyrrhiza glabra −90.7 −103.1
licoagrochalcone D Glycyrrhiza glabra −14.6 −100.5
licochalcone A Glycyrrhiza glabra −93.2 −107.8
licochalcone B Glycyrrhiza glabra −107.8 −108.9
α,2′,4,4′-tetrahydroxydihydrochalcone Glycyrrhiza glabra −98.3 −105.0
2,4,4′-trihydroxychalcone Glycyrrhiza glabra −103.4 −104.9
xanthohumol Glycyrrhiza glabra −116.8 −116.8
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Table 4 MolDock molecular docking energies (kJ/mol) for coumarins with human estrogen receptors α and β
Compound Plant Source ERα ERβ
7-acetoxy-4-methylcoumarin Trigonella foenum-graecum −74.6 −77.6
bergapten Glycyrrhiza glabra −71.2 −77.6
coumestrol Glycyrrhiza glabra −89.4 −99.8
Trifolium pratense
3,4-didehydroglabridin Glycyrrhiza glabra −34.7 −90.0
6α,7-dihydroxymaackiain Trifolium pratense −97.7 −107.9
gancaonin F Glycyrrhiza glabra −37.5 −109.6
glabrene Glycyrrhiza glabra −104.8 −114.9
glabrocoumarin Glycyrrhiza glabra −99.0 −109.7
glycycoumarin Glycyrrhiza glabra −75.2 −110.2
glycyrol Glycyrrhiza glabra −49.2 −108.8
glyinflanin H Glycyrrhiza glabra −53.3 −102.1
hispaglabridin A Glycyrrhiza glabra −68.5 −84.3
hispaglabridin B Glycyrrhiza glabra −42.8 −59.3
6α-hydroxymaackiain Trifolium pratense −95.9 −102.9
3′-hydroxy-4′-methoxyglabridin Glycyrrhiza glabra −35.9 −86.9
isoglycycoumarin Glycyrrhiza glabra −20.3 −77.6
isoglycyrol Glycyrrhiza glabra −10.8 −66.1
kanzonol U Glycyrrhiza glabra −102.8 −109.9
kanzonol V Glycyrrhiza glabra −23.7 −71.3
kanzonol W Glycyrrhiza glabra −20.4 −82.5
licocoumarin A Glycyrrhiza glabra −54.9 −24.2
maackiain Trifolium pratense −84.3 −83.6
medicagol Trifolium pratense −91.6 −107.6
medicarpin Trifolium pratense −83.7 −79.1
9-O-methylcoumestrol Trifolium pratense −88.2 −100.8
2′-O-methylglabridin Glycyrrhiza glabra −78.7 −78.2
4′-O-methylgrabridin Glycyrrhiza glabra −25.4 −80.8
4′-O-methylkanzonol W Glycyrrhiza glabra no dock −69.4
mirificoumestan Pueraria mirifica −98.9 −113.0
pisatin Trifolium pratense −84.7 −96.8
pratenol A Trifolium pratense −93.7 −99.4
pratenol B Trifolium pratense −104.8 −112.0
trifolian Trifolium pratense −82.0 −71.9
trigocoumarin Trigonella foenum-graecum −93.6 −98.1
trigoforin Trigonella foenum-graecum −59.0 −66.2
variabilin Trifolium pratense −86.5 −86.9
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Table 5 MolDock molecular docking energies (kJ/mol) for diterpenoids with human estrogen receptors α and β
Compound Plant Source ERα ERβ
antadiosbulbin A Dioscorea spp. −102.7 −68.7
antadiosbulbin B Dioscorea spp. −76.0 −64.9
bafoudiosbulbin A Dioscorea spp. −102.2 −79.3
bafoudiosbulbin B Dioscorea spp. −95.6 −98.9
bafoudiosbulbin C Dioscorea spp. −68.0 −93.1
bafoudiosbulbin D Dioscorea spp. −79.3 −75.8
bafoudiosbulbin E Dioscorea spp. −84.1 −62.2
bafoudiosbulbin F Dioscorea spp. −86.0 −73.6
bafoudiosbulbin_G Dioscorea spp. −56.3 −13.0
6α,7α-dihydroxyannonene Ptychopetalum olacoides, P. uncinatum −95.2 −107.3
7,20-dihydroxyannonene Ptychopetalum olacoides, P. uncinatum −91.8 −105.5
6,7-dihydroxykolavenol Ptychopetalum olacoides, P. uncinatum −94.0 −107.0
diosbulbin A Dioscorea spp. −82.3 −47.7
diosbulbin B Dioscorea spp. −86.7 −81.8
diosbulbin C Dioscorea spp. −83.9 −50.1
diosbulbin D Dioscorea spp. −107.1 −110.4
diosbulbin E Dioscorea spp. −92.2 −108.1
diosbulbin F Dioscorea spp. −111.2 −114.8
diosbulbin G Dioscorea spp. −89.9 −72.0
diosbulbin H Dioscorea spp. −97.5 −114.1
diosbulbin I Dioscorea spp. no dock no dock
diosbulbin J Dioscorea spp. −106.4 −107.1
diosbulbin K Dioscorea spp. −112.1 −108.3
diosbulbin L Dioscorea spp. −110.8 −110.9
diosbulbin M Dioscorea spp. −103.1 −107.8
8-epidiosbulbin E Dioscorea spp. −78.3 −72.8
8-epidiosbulbin E acetate Dioscorea spp. −16.8 −35.0
8-epidiosbulbin G Dioscorea spp. −89.3 −72.8
15,16-epoxy-6,8-dihydroxy-19-nor-13(16),14-clerodadiene-17,12:18,2-diolide-6-acetate Dioscorea spp. −38.1 −26.8
7-hydroxykolavelool Ptychopetalum olacoides, P. uncinatum −90.7 −100.1
7-hydroxysolidagolactone Ptychopetalum olacoides, P. uncinatum −96.1 −109.4
kolavelool Ptychopetalum olacoides, P. uncinatum −89.4 −94.8
8,14-labdadiene-6,7,13-triol-6,7-diacetate Vitex agnus-castus −92.4 −90.7
20-O-methylptychonal acetal Ptychopetalum olacoides, P. uncinatum −92.6 −105.1
7-oxokolavelool Ptychopetalum olacoides, P. uncinatum −91.6 −99.7
ptycho-6α,7α-diol Ptychopetalum olacoides, P. uncinatum −103.6 −122.9
ptycholide I Ptychopetalum olacoides, P. uncinatum −101.0 −108.9
ptycholide II Ptychopetalum olacoides, P. uncinatum −105.1 −104.6
ptycholide III Ptychopetalum olacoides, P. uncinatum −98.6 −109.1
ptycholide IV Ptychopetalum olacoides, P. uncinatum −103.7 −114.7
ptychonal Ptychopetalum olacoides, P. uncinatum −93.8 −104.7
ptychonal (hemiacetal) Ptychopetalum olacoides, P. uncinatum −93.4 −105.9
ptychonolide Ptychopetalum olacoides, P. uncinatum −87.7 −99.9
viteagnuside A (aglycone) Vitex agnus-castus −100.1 −101.9
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Table 5 MolDock molecular docking energies (kJ/mol) for diterpenoids with human estrogen receptors α and β (Continued)
viteagnusin A Vitex agnus-castus −87.4 −94.6
viteagnusin_B Vitex agnus-castus −75.5 −95.6
viteagnusin D Vitex agnus-castus −92.4 −97.3
viteagnusin E Vitex agnus-castus −3.7 −37.0
viteagnusin F Vitex agnus-castus −7.1 no dock
viteagnusin G Vitex agnus-castus −44.3 −76.4
viteagnusin H Vitex agnus-castus −93.5 −94.3
viteagnusin I Vitex agnus-castus −44.2 −46.1
viteagnusin J Vitex agnus-castus −54.5 −93.5
vitexlactam A Vitex agnus-castus −102.4 −99.1
Table 6 MolDock molecular docking energies (kJ/mol) for flavonoids with human estrogen receptors α and β
Compound Plant Source ERα ERβ
acacetin Ginkgo biloba −83.6 −96.0
Turnera aphrodisiaca
Turnera diffusa
amentoflavone Ginkgo biloba no dock no dock





bilobetin Ginkgo biloba no dock no dock
6"-caffeoylisoorientin Vitex agnus-castus no dock no dock
6"-caffeoylisoorientin(4"-methylether) Vitex agnus-castus no dock no dock
8-(5-carboxy-2-methoxyphenyl)-5,7-dihydroxy-4"-methoxyflavone Ginkgo biloba −50.1 −78.2
casticin Centella asiatica −15.6 −106.4
Vitex agnus-castus
castillicetin Centella asiatica −59.1 −89.5
castilliferol Centella asiatica −48.5 −85.2
chrysin Ginkgo biloba −81.6 −88.2
chrysoeriol Silybum marianum −94.6 −102.6
cisilandrin Silybum marianum no dock no dock
2"-O-p-coumaroylorientin Trigonella foenum-gracum no dock no dock
2"-O-p-coumaroylvitexin Trigonella foenum-gracum no dock no dock
cyanidin Ginkgo biloba −89.1 −101.9
Trifolium pratense
2,3-dehydrosilybin Silybum marianum no dock no dock
2,3-dehydrosilychristin Silybum marianum no dock no dock
delphinidin Trifolium pratense −91.6 −102.3
5-O-demethyltangeretin Vitex agnus-castus −61.5 −101.1
6,8-digalactosylapigenin Trigonella foenum-gracum no dock no dock
diosmetin Turnera aphrodisiaca −87.8 −102.0
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Table 6 MolDock molecular docking energies (kJ/mol) for flavonoids with human estrogen receptors α and β (Continued)
Turnera diffusa
epigallocatechin Ginkgo biloba −88.1 −80.5
eriodictyol Silybum marianum −89.1 −101.3
folerogenin Glycyrrhiza glabra −78.2 −71.4
8-galactopyranosyl-6-quinovopyranosylapigenin Trigonella foenum-graecum no dock no dock
8-galactopyranosyl-6-xylopyranosylapigenin Trigonella foenum-graecum no dock no dock
garbanzol Trifolium pratense −84.7 −83.6
ginkgetin Ginkgo biloba no dock no dock
glabranin Glycyrrhiza glabra −90.3 −94.3
glabrol Glycyrrhiza glabra −96.1 −97.4
gonzalitosin Turnera aphrodisiaca −71.7 −106.3
Turnera diffusa
gossypetin Rhodiola rosea −98.6 −105.7
(2R,3S,4S)-3,3′,4,4′,5,5′,7-heptahydroxyflavan Ginkgo biloba −89.9 −82.8
herbacetin Rhodiola rosea −94.6 −102.1
3-hydroxyglabrol Glycyrrhiza glabra −68.9 −101.5
isocisilandrin Silybum marianum no dock no dock
isoginkgetin Ginkgo biloba no dock no dock
isolicoflavonol Glycyrrhiza glabra −97.0 −102.0
isoorientin Tribulus terrestris no dock no dock
Trigonella foenum-graecum
Vitex agnus-castus
isorhamnetin Trifolium pratense −95.2 −103.4
isoschaftoside Glycyrrhiza glabra no dock no dock
isosilandrin A Silybum marianum no dock no dock
isosilandrin B Silybum marianum no dock no dock
isosilybin A Silybum marianum no dock no dock
isosilybin B Silybum marianum no dock no dock
isosilybin C Silybum marianum no dock no dock
isosilybin D Silybum marianum no dock no dock
isosilychristin Silybum marianum no dock −69.6
isoviolanthin Glycyrrhiza glabra −44.1 no dock
isovitexin Trigonella foenum-graecum no dock −6.7
Vitex agnus-castus
isoxanthohumol Humulus lupulus −102.5 −99.6






kumatakenin Glycyrrhiza glabra −88.3 −101.2
laricitrin Turnera aphrodisiaca −90.4 −107.3
Turnera diffusa
licoagrodin Glycyrrhiza glabra no dock no dock
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Table 6 MolDock molecular docking energies (kJ/mol) for flavonoids with human estrogen receptors α and β (Continued)
licoflavanone Glycyrrhiza glabra −95.2 −102.2
liquiritigenin Glycyrrhiza glabra −84.9 −97.1
luteolin Trigonella foenum-graecum −92.0 −103.5
Vitex agnus-castus
luteolin-8-propenoic acid Turnera aphrodisiaca −113.1 −123.1
Turnera diffusa
malvidin Trifolium pratense −86.0 −99.9
5′-methoxybilobetin Ginkgo biloba no dock no dock
myricetin Trifolium pratense −90.7 −106.2
naringenin Glycyrrhiza glabra −86.3 −95.4
Silybum marianum
neocorymboside Trigonella foenum-graecum no dock no dock
neosilyhermin A Silybum marianum −42.8 −44.5
neosilyhermin B Silybum marianum no dock −67.6
norwogonin Glycyrrhiza glabra −83.7 −91.9




orientin-3"-ketone Turnera aphrodisiaca −83.8 −74.3
Turnera diffusa
pectolinarigenin Trifolium pratense −84.8 −99.7
peonidin Ginkgo biloba −94.0 −100.5
Trifolium pratense
pinocembrin Glycyrrhiza glabra −81.4 −88.1
Turnera aphrodisiaca
Turnera diffusa
6-prenyleriodictyol Glycyrrhiza glabra −82.1 −91.2
8-prenyleriodictyol Glycyrrhiza uralensis −102.9 −87.7
6-prenylnaringenin Glycyrrhiza glabra −62.8 −91.7
8-prenylnaringenin Humulus lupulus −99.2 −102.8
6-prenylpinocembrin Glycyrrhiza glabra −49.1 −89.1






rhodiolin Rhodiola rosea no dock no dock
santin Vitex agnus-castus −31.3 −107.9
sciadopitysin Ginkgo biloba no dock no dock
shinflavanone Glycyrrhiza glabra −63.1 −77.4
sigmoidin B Glycyrrhiza uralensis −35.5 −92.7
silandrin A Silybum marianum no dock no dock
silandrin B Silybum marianum no dock no dock
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Table 6 MolDock molecular docking energies (kJ/mol) for flavonoids with human estrogen receptors α and β (Continued)
silyamandin Silybum marianum no dock no dock
silybin A Silybum marianum no dock no dock
silybin B Silybum marianum no dock no dock
silychristin Silybum marianum no dock no dock
silychristin B Silybum marianum −69.2 no dock
silydianin Silybum marianum no dock −73.5
silyhermin Silybum marianum no dock 72.2
silymonin Silybum marianum no dock −69.2
syringetin Turnera aphrodisiaca −80.5 −95.1
Turnera diffusa
taxifolin Silybum marianum −89.4 −104.6
3,4′,5,8-tetrahydroxyflavone Trifolium pratense −92.0 −103.1
tricetin Ginkgo biloba −86.2 −106.2
trigraecum Trigonella foenum-graecum −82.7 −94.4
vicenin 1 Trigonella foenum-graecum no dock no dock
vicenin 2 Trigonella foenum-graecum no dock no dock
vicenin 3 Trigonella foenum-graecum no dock no dock
vitexin Glycyrrhiza glabra −83.7 −88.5
Vitex agnus-castus
Table 7 MolDock molecular docking energies (kJ/mol) for isoflavonoids with human estrogen receptors α and β
Compound Plant Source ERα ERβ
7-acetoxy-2-methylisoflavone Glycyrrhiza glabra −78.4 −94.9
biochanin A Trifolium pratense −90.2 −98.6
calycosin Trifolium pratense −86.0 −103.3
daidzein Trifolium pratense −88.1 −95.0
formononetin Cimicifuga racemosa −83.5 −98.5
genistein Glycyrrhiza glabra −93.4 −98.9
Trifolium pratense
glabraisoflavanone A Glycyrrhiza glabra no dock no dock
glabraisoflavanone B Glycyrrhiza glabra no dock no dock
glabridin Glycyrrhiza glabra −15.8 −92.9
glabroisoflavanone A Glycyrrhiza glabra −35.5 −87.5
glabroisoflavanone B Glycyrrhiza glabra −29.1 −100.1
glabrone Glycyrrhiza glabra −39.0 −87.5
glyasperin B Glycyrrhiza glabra −81.7 −90.1
glyasperin K Glycyrrhiza glabra −35.4 −64.0
glyzaglabrin Glycyrrhiza glabra −99.1 −103.9
glyzarin Glycyrrhiza glabra −93.3 −94.2
7-hydroxy-2-methylisoflavone Glycyrrhiza glabra −79.0 −87.3
irilone Trifolium pratense −87.4 −102.8
isoderrone Glycyrrhiza glabra −27.5 −84.1
Powers and Setzer In Silico Pharmacology  (2015) 3:4 Page 49 of 63
Table 7 MolDock molecular docking energies (kJ/mol) for isoflavonoids with human estrogen receptors α and β
(Continued)
isoglabrone Glycyrrhiza glabra −34.1 −75.1
isomucronulatol Glycyrrhiza glabra −87.1 −104.4
kanzonol R Glycyrrhiza glabra −82.9 −101.7
kanzonol T Glycyrrhiza glabra no dock no dock
kanzonol X Glycyrrhiza glabra −54.9 −51.2
licoagroside A (aglycone) Glycyrrhiza glabra −100.5 −107.7
licoricidin Glycyrrhiza glabra −41.5 no dock
lupiwighteone Glycyrrhiza glabra −96.1 −107.8
7-methoxy-2-methylisoflavone Glycyrrhiza glabra −79.2 −86.9
1-methoxyphaseollin Glycyrrhiza glabra −76.2 −110.5
phaseollinisoflavan Glycyrrhiza glabra −63.7 −89.4
pratensein Trifolium pratense −93.7 −106.4
8-prenylphaseollinisoflavan Glycyrrhiza glabra no dock −43.2
prunetin Glycyrrhiza glabra −92.8 −98.9
pseudobaptigenin Trifolium pratense −94.6 −104.1
shinpterocarpin Glycyrrhiza glabra −65.3 −95.1
2′,4′,5,7-tetrahydroxy-3′,8-diprenylisoflavanone Glycyrrhiza glabra −37.0 −34.8
tetrapterol G Glycyrrhiza glabra −49.9 −100.8
3′,5,7-trihydroxy-5′-methoxyisoflavone Trigonella foenum-graecum −97.4 −107.9
wighteone Glycyrrhiza glabra −75.8 −101.9
vitexcarpan Vitex agnus-castus −70.4 −99.5
Table 8 MolDock molecular docking energies (kJ/mol) for lignans with human estrogen receptors α and β
Compound Plant Source ERα ERβ
actaealactone Cimicifuga racemosa −102.8 −112.3
(−)-arctigenin Arctium lappa −109.9 −116.2
(Z)-dehydrodiconiferyl alcohol Silybum marianum −97.9 −110.6
dihydrodehydrodiconiferyl alcohol (9-acetate) Sambucus nigra −102.7 −97.5
7′-hydroxymatairesinol Podocarpus spicatus −112.3 −117.3
isolariciresinol Picea excelsa −76.2 −84.6
(+)-lariciresinol Rhodiola rosea −104.2 −113.7
licoagrocarpin Glycyrrhiza glabra −90.4 −85.4
nordihydroguaiaretic acid Guaiacum officinale −102.1 −106.4
(−)-nortrachelogenin Pinus palustris −112.0 −125.4
pinoresinol Picea excelsa −106.4 −117.7
secoisolariciresinol Picea abies −109.1 −114.2
sesamin Ginkgo biloba −99.1 −121.8
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Table 9 MolDock molecular docking energies (kJ/mol) for phenanthrenoids with human estrogen receptors α and β
Compound Plant Source ERα ERβ
batatasin I Dioscorea spp. −84.7 −97.1
denthyrsinin Dioscorea spp. −83.5 −96.7
9,10-dihydro-2,7-dihydroxy-1,3,5-trimethoxyphenanthrene Dioscorea spp. −80.8 −95.7
9,10-dihydro-5,7-dimethoxy-3,4-phenanthrenediol Dioscorea spp. −81.0 −90.1
9,10-dihydro-2,3,5,7-phenanthrenetetrol Dioscorea spp. −78.0 −83.2
9,10-dihydro-4,6,7-trimethoxy-2-phenanthrenol Dioscorea spp. −88.5 −99.6
9,10-dihydro-5,6,8-trimethoxy-3,4-phenanthrenediol Dioscorea spp. −72.9 −87.5
6,7-dihydroxy-2-methoxy-1,4-phenanthraquinone Dioscorea spp. −85.9 −94.9
3,5-dimethoxy-2,7-phenanthrenediol Dioscorea spp. −84.6 −93.5
5,7-dimethoxy-2,3-phenanthrenediol Dioscorea spp. −88.5 −93.6
diobulbinone Dioscorea spp. no dock no dock
dioscoreanone Dioscorea spp. −88.6 −96.1
hircinol Dioscorea spp. −68.9 −76.3
6-methoxycoelonin Dioscorea spp. −83.5 −93.9
2,4,5,6-phenanthrenetetrol Dioscorea spp. −74.7 −82.9
3,4,6-phenanthrenetriol Dioscorea spp. −74.3 −79.9
prazerol Dioscorea spp. −84.6 −96.5
Table 10 MolDock molecular docking energies (kJ/mol) for miscellaneous phenolic ligands with human estrogen
receptors α and β
Compound Plant Source ERα ERβ
agnucastoside C (aglycone) Vitex agnus-castus −106.9 −130.0
agnuside (aglycone) Vitex agnus-castus −103.1 −110.3
angeliferulate Angelica sinensis −110.7 −121.5
1,3-bis(2,4-dihydroxyphenyl)propane Dioscorea spp. −101.7 −101.1
1,3-bis(2-hydroxy-4-methoxyphenyl)propane Dioscorea spp. −97.1 −94.9
burkinabin A Echinacea spp. −97.6 −100.6
burkinabin B Echinacea spp. −101.2 −85.1
caffeic acid Echinacea spp. −72.1 −74.5
caffeoyl-p-coumaroyltartaric acid Echinacea spp. −98.3 −129.8
caffeoylferuloyltartaric acid Echinacea spp. −76.1 −96.2
trans-caffeoylglycolic acid Cimicifuga racemosa −87.3 −96.7
caftaric acid Echinacea spp. −105.7 −112.1
chicoric acid Echinacea spp. −99.1 −116.1
cimicifugic acid A Cimicifuga racemosa −102.9 −124.1
cimicifugic acid B Cimicifuga racemosa −114.4 −120.5
cimicifugic acid F Cimicifuga racemosa −126.2 −125.2
cimicifugic acid G Cimicifuga racemosa −101.4 −113.4
cimiciphenol Cimicifuga racemosa −113.2 −119.4
cimiciphenone Cimicifuga racemosa −109.0 −120.8
cimifugin Cimicifuga racemosa −93.6 −97.1
cimiracemate A Cimicifuga racemosa −113.9 −120.9
cimiracemate B Cimicifuga racemosa −114.4 −127.3
cimiracemate C Cimicifuga racemosa −110.5 −115.8
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Table 10 MolDock molecular docking energies (kJ/mol) for miscellaneous phenolic ligands with human estrogen
receptors α and β (Continued)
cimiracemate D Cimicifuga racemosa −104.2 −128.5
p-coumaric acid Trigonella foenum-graecum −65.8 −69.0
diferuloyltartaric acid Echinacea spp. −102.6 −88.7
6,7-dihydroxy-1,1-dimethylisochroman Dioscorea spp. −68.4 −67.5
2-(3,7-dimethyl-2,6-octadienyl)-4-hydroxy-6-methoxyacetophenone Dioscorea spp. −99.6 −104.8
ferulic acid Echinacea spp. −70.7 −78.2
fukiic acid Cimicifuga racemosa −83.4 −88.1
fukinolic acid Cimicifuga racemosa −113.6 −127.3
irbic acid Centella asiatica no dock −17.6
isoferulic acid Cimicifuga racemosa −68.6 −73.7
licoagroaurone Glycyrrhiza glabra −109.5 −117.9
licoagrone Glycyrrhiza glabra no dock no dock
paeonol Dioscorea spp. −59.4 −62.5
(S)-phaselic acid Trifolium pratense −99.7 −109.6
trichocarpinine Echinacea spp. −84.4 −92.4
Table 11 MolDock molecular docking energies (kJ/mol) for sesquiterpenoids with human estrogen receptors α and β
Compound Plant Source ERα ERβ
bilobanol Ginkgo biloba −84.8 −89.2
bisabolangelone Angelica sinensis −80.2 −90.4
cinnamoyldihydroxynardol Echinacea spp. −99.5 −98.5
cinnamoylechinadiol Echinacea spp. −83.6 −120.8
cinnamoylechinaxanthol Echinacea spp. −87.6 −94.9
cinnamoylepoxyechinadiol Echinacea spp. −86.4 −107.9
Table 12 MolDock molecular docking energies (kJ/mol) for steroids with human estrogen receptors α and β
Compound Plant Source ERα ERβ






chiapagenin Dioscorea spp. −61.5 no dock
chlorogenin Tribulus terrestris −5.7 no dock
cholest-5-ene-3,12,16,22-tetrol Dioscorea spp. −49.5 −82.0
correllogenin Dioscorea spp. −64.3 no dock
cryptogenin Dioscorea spp. −51.3 −74.8
2,3-dihydroxypregn-16-en-20-one Tribulus terrestris −105.3 −116.6
2,3-dihydroxyspirost-4-en-12-one Tribulus terrestris no dock no dock
3,16-dihydroxypregn-5-en-20-one Dioscorea spp. −91.9 −116.6
3,16-dihydroxypregnane-12,20-dione Tribulus terrestris −93.7 −95.6
3,21-dihydroxypregna-5,16-dien-20-one Dioscorea spp. −103.1 −121.4
diosbulbisin A Dioscorea spp. no dock no dock
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Table 12 MolDock molecular docking energies (kJ/mol) for steroids with human estrogen receptors α and β (Continued)
diosbulbisin B Dioscorea spp. no dock no dock
diosbulbisin C Dioscorea spp. no dock no dock
diosbulbisin D Dioscorea spp. −59.9 no dock
diosgenin Dioscorea spp. −58.9 no dock
Tribulus terrestris
Trigonella foenum-graecum
diosgenin acetate Dioscorea spp. no dock no dock
diotigenin Dioscorea spp. no dock no dock
doristerol Dioscorea spp. −62.1 −80.3
episarsasapogenin Dioscorea spp. no dock no dock
epismilagenin Dioscorea spp. −53.4 no dock
ergost-5-ene-3,26-diol Dioscorea spp. −71.3 −108.6
ergost-8(14)-en-3-ol Dioscorea spp. −69.5 −98.5
furost-20(22)-ene-2,3,26-triol Tribulus terrestris −37.8 −44.1
furost-20(22)-ene-3,26-diol Tribulus terrestris −10.1 −45.5
furost-5-ene-3,16,26-triol Tribulus terrestris −49.7 −45.8
furost-5-ene-3,22,26,27-tetrol Dioscorea spp. −35.1 −4.6
furost-5-ene-3,22,26-triol Dioscorea spp. −48.2 −24.1
Tribulus terrestris
furosta-5,20(22)-diene-3,26-diol Dioscorea spp. −30.4 −36.0
furostane-1,2,3,22,26-pentol Dioscorea spp. −40.7 −51.4
gentrogenin Dioscorea spp. −49.8 no dock
gitogenin Tribulus terrestris no dock no dock
Trigonella foenum-graecum
globosterol Ginkgo biloba −31.4 −11.3
hecogenin Tribulus terrestris no dock no dock
26-hydroxyfurosta-4,20(22)-diene-3,12-dione Tribulus terrestris −20.2 −32.5
24-hydroxyspirost-4-ene-3,12-dione Tribulus terrestris no dock no dock
19-hydroxyyonogenin Dioscorea spp. no dock no dock
igagenin Dioscorea spp. −41.8 no dock
isochiapagenin Dioscorea spp. −49.1 no dock
isodiotigenin Dioscorea spp. −54.5 no dock
isonarthogenin Dioscorea spp. −61.3 no dock
kogagenin Dioscorea spp. −56.5 no dock
marianine Silybum marianum −5.9 −57.3
24-methylenelanost-8-ene-3,25,28-triol Silybum marianum −29.3 −38.3
neogitogenin Tribulus terrestris −55.1 no dock
neohecogenin Tribulus terrestris −39.7 no dock
neokammogenin Dioscorea spp. no dock no dock
neotigogenin Tribulus terrestris −51.9 no dock
Trigonella foenum-graecum
neoyonogenin Dioscorea spp. no dock no dock
pentandroside F (aglycone) Tribulus terrestris −37.5 −41.4
Trigonella foenum-graecum
prazerigenin A Dioscorea spp. −56.1 no dock
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Table 12 MolDock molecular docking energies (kJ/mol) for steroids with human estrogen receptors α and β (Continued)
prazerigenin B Dioscorea spp. −53.2 no dock
prazerigenin C Dioscorea spp. −60.7 no dock
pregnadienolone Dioscorea spp. −102.7 −115.4
protoyonogenin (aglycone) Dioscorea spp. −28.9 −17.8
ruscogenin Tribulus terrestris −6.9 no dock
sarsasapogenone Dioscorea spp. −51.4 no dock
β-sitosterol Tribulus terrestris −65.0 −102.8
smilagenone Dioscorea spp. no dock no dock
25R-spirosta-3,5-diene Trigonella foenum-graecum −54.8 no dock
spirost-4-ene-3,12-dione Tribulus terrestris −67.9 no dock
spirost-4-ene-3,6,12-trione Tribulus terrestris no dock no dock
spirosta-3,5-dien-12-one Tribulus terrestris −50.5 no dock
spirostane-3,23,24-triol Tribulus terrestris no dock no dock
spirostane-3,6,12-trione Tribulus terrestris no dock no dock
steroid G4 Dioscorea spp. no dock no dock
stigmast-8(14)-en-3-ol Dioscorea spp. −45.3 −75.3
terrestrosin K (aglycone) Tribulus terrestris no dock −60.5
1,2,3,16-tetrahydroxypregnan-20-one Dioscorea spp. −88.7 −48.9
tigogenin Tribulus terrestris no dock no dock
Trigonella foenum-graecum
tokorogenin Dioscorea spp. −50.3 no dock
tribufuroside C (aglycone) Tribulus terrestris no dock −65.4
tribufuroside D (aglycone) Tribulus terrestris no dock −13.1
tribufuroside I (aglycone) Tribulus terrestris −2.9 −35.0
tribufuroside J (aglycone) Tribulus terrestris no dock −34.3
trigoneoside (aglycone) Trigonella foenum-graecum −53.8 −55.6
2,3,4-trihydroxypregn-16-en-20-one Dioscorea spp. −82.7 −71.9
yamogenin Dioscorea spp. −59.4 no dock
Trigonella foenum-graecum
yonogenin Dioscorea spp. no dock no dock
Table 13 MolDock molecular docking energies (kJ/mol) for stilbenoids with human estrogen receptors α and β
Compound Plant Source ERα ERβ
3-acetoxy-4′,5-dihydroxy-3′-prenyldihydrostilbene Glycyrrhiza glabra −119.0 −118.7
batatasin II Dioscorea spp. −84.6 −94.7
batatasin III Dioscorea spp. −83.3 −92.6
batatasin IV Dioscorea spp. −80.7 −93.4
batatasin V Dioscorea spp. −88.6 −98.4
demethylbatatasin IV Dioscorea spp. −81.1 −92.3
dihydropinosylvin Dioscorea spp. −77.9 −86.2
dihydropinosylvin methyl ether Dioscorea spp. −74.1 −89.3
dihydroresveratrol Dioscorea spp. −83.0 −94.4
2,4′-dihydroxy-3′,5′-dimethoxybibenzyl Dioscorea spp. −87.4 −100.3
gancaonin R Glycyrrhiza uralensis −102.1 −107.0
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Table 13 MolDock molecular docking energies (kJ/mol) for stilbenoids with human estrogen receptors α and β
(Continued)
licoagrodione Glycyrrhiza glabra −98.2 −116.9
piceatannol Picea abies −85.9 −100.3
3,3′,4,5′-tetrahydroxy-4′,5-diprenylbibenzyl Glycyrrhiza glabra −108.9 −117.1
2,2′,5,5′-tetrahydroxy-3-methoxybibenzyl Dioscorea spp. −87.4 −99.0
3,3′,4,5′-tetrahydroxy-5-prenylbibenzyl Glycyrrhiza glabra −111.4 −115.0
3,3′,5′-trihydroxy-4-methoxybibenzyl Glycyrrhiza glabra −88.0 −97.7
3,4′,5-trihydroxy-3′,4-diprenylbibenzyl Glycyrrhiza glabra −107.4 −111.0
3,3′,5′-trihydroxy-4-methoxy-5-prenylbibenzyl Glycyrrhiza glabra −111.4 −113.6
3,4′,5-trihydroxy-3′-prenyldihydrostilbene Glycyrrhiza glabra −106.3 −112.0
tristin Dioscorea spp. −91.1 −98.7
uralstilbene Glycyrrhiza glabra −101.7 −122.1
Table 14 MolDock molecular docking energies (kJ/mol) for triterpenoids with human estrogen receptors α and β
Compound Plant Source ERα ERβ
actaeaepoxide Cimicifuga racemosa no dock no dock
acteol Cimicifuga racemosa −18.4 no dock
acteol-12-acetate Cimicifuga racemosa no dock no dock
acteol-26-ketone Cimicifuga racemosa −42.3 no dock
12β-acetoxycimigenol Cimicifuga racemosa no dock no dock
25-acetoxy-12β-hydroxycimigenol Cimicifuga racemosa no dock no dock
24-acetoxyisodahurinol Cimicifuga racemosa no dock no dock
23-acetoxyshengmanol Cimicifuga racemosa no dock no dock
3′-acetylcimicifugoside (aglycone) Cimicifuga racemosa −30.4 −25.5
α-amyrin Sambucus nigra no dock −5.6
β-amyrin Glycyrrhiza glabra no dock no dock
α-amyrone Sambucus nigra no dock no dock
25-anhydrocimigenol-12β-acetoxy Cimicifuga racemosa no dock no dock
asiatic acid Centella asiatica no dock no dock
asiaticoside G (aglycone) Centella asiatica no dock no dock
betulafolienetriol Centella asiatica −73.1 −67.8
betulin Sambucus nigra no dock −26.3
betulinic acid Glycyrrhiza glabra no dock −43.9
caulophyllogenin Cimicifuga racemosa no dock no dock
centellasapogenol A Centella asiatica no dock no dock
centelloside A (aglycone) Centella asiatica −59.8 −75.5
cimicidol-3-one Cimicifuga racemosa −47.0 −65.6
cimigenol Cimicifuga racemosa no dock no dock
cimipodocarpaside (aglycone) Cimicifuga racemosa −28.8 −4.4
cimiracemoside F (aglycone) Cimicifuga racemosa no dock no dock
cimiracemoside H (aglycone) Cimicifuga racemosa no dock no dock
cimiracemoside I (aglycone) Cimicifuga racemosa −66.2 no dock
corosolic acid Centella asiatica no dock no dock
9(11)-dehydroglycyrrhetic acid Glycyrrhiza glabra no dock no dock
26-deoxyacteol Cimicifuga racemosa −39.7 no dock
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Table 14 MolDock molecular docking energies (kJ/mol) for triterpenoids with human estrogen receptors α and β
(Continued)
11-deoxoglycyrrhetic acid Glycyrrhiza glabra no dock no dock
desoxoglabrolide Glycyrrhiza glabra no dock no dock
12β,21-dihydroxycimigenol Cimicifuga racemosa no dock no dock
2,3-dihydroxy-5-(hydroxymethyl)-24-norolean-12-en-28-oic acid Centella asiatica no dock no dock
3,24-dihydroxy-11,13(18)-oleanadien-30-oic acid methyl ester Glycyrrhiza glabra no dock no dock
3,24-dihydroxy-9(11),12-oleanadien-30-oic acid Glycyrrhiza glabra no dock no dock
23-epi-26-deoxyacteol Cimicifuga racemosa −53.0 no dock
glabric acid Glycyrrhiza glabra no dock no dock
glabrolide Glycyrrhiza glabra no dock no dock
glycyrrhetic acid Glycyrrhiza glabra no dock no dock
18α-glycyrrhetic acid Glycyrrhiza glabra no dock no dock
glycyrrhetol Glycyrrhiza glabra no dock no dock
21-hydroxycimigenol Cimicifuga racemosa no dock no dock
18α-hydroxyglycyrrhetic acid Glycyrrhiza glabra no dock no dock
24-hydroxyglycyrrhetic acid Glycyrrhiza glabra no dock no dock
28-hydroxyglycyrrhetic acid Glycyrrhiza glabra no dock no dock
21-hydroxyisoglabrolide Glycyrrhiza glabra no dock no dock
24-hydroxyliquiritic acid Glycyrrhiza glabra no dock no dock
6β-hydroxymaslinic acid Centella asiatica no dock no dock
isoglabrolide Glycyrrhiza glabra no dock no dock
isothankunic acid Centella asiatica no dock no dock
lanosta-5,24-dien-3-ol Glycyrrhiza glabra −55.6 −52.3
liquiridiolic acid Glycyrrhiza glabra no dock no dock
liquiritic acid Glycyrrhiza glabra no dock no dock
liquoric acid Glycyrrhiza glabra no dock no dock
lupeol Ptychopetalum olacoides no dock −40.5
P. uncinatum
Sambucus nigra
madasiatic acid Centella asiatica no dock no dock
madecassic acid Centella asiatica no dock no dock
neocimicigenol Cimicifuga racemosa no dock no dock
oleanolic acid Sambucus nigra no dock no dock
quasipanaxadiol Centella asiatica no dock −35.5
shengmanol Cimicifuga racemosa no dock −3.0
silymin A Sambucus nigra no dock no dock
silymin B Sambucus nigra no dock no dock
terminolic acid Centella asiatica no dock no dock
2,3,20,23-tetrahydroxy-28-ursanoic acid Centella asiatica no dock no dock
2,3,23-trihydroxy-20-ursen-28-oic acid Centella asiatica no dock no dock
3,6,23-trihydroxy-12-ursen-28-oic acid Centella asiatica no dock no dock
uncargenin C Centella asiatica no dock no dock
ursolic acid Sambucus nigra no dock no dock
zemoside A (aglycone) Centella asiatica no dock no dock
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Table 15 MolDock molecular docking energies (kJ/mol) for miscellaneous phytochemicals with human estrogen
receptors α and β
Compound Plant Source ERα ERβ
10-angeloylbutylphthalide Angelica sinensis −96.9 −107.1
ansaspirolide Angelica sinensis −98.5 −91.5
asiaticin Centella asiatica −96.7 −109.0
3a,7′a:7a,3′a-diligustilide Angelica sinensis −94.5 −69.6
3a,8′:6,3′-diligustilide Angelica sinensis −91.3 −72.6
3a,8′:6,3′-diligustilidetriepimer Angelica sinensis −98.0 −78.1
dioscorealide A Dioscorea spp. −92.1 −97.1
dioscorealide B Dioscorea spp. −86.2 −98.7
diospongin A Dioscorea spp. −95.1 −104.8
diospongin B Dioscorea spp. −97.1 −103.9
diospongin C Dioscorea spp. −96.1 −107.9
gelispirolide Angelica sinensis −64.7 −84.8
homosenkyunolide H Angelica sinensis −83.8 −88.7
homosenkyunolide I Angelica sinensis −84.3 −92.2
homosilphiperfoloic acid Centella asiatica −83.0 −77.3
levistolide A Angelica sinensis −86.5 −86.4
neodiligustilide Angelica sinensis −78.3 −6.6
orobanchyl acetate Trifolium pratense −111.3 −122.8
riligustilide Angelica sinensis −71.2 −81.6
senkyunolide O Angelica sinensis −84.8 −91.3
sinaspirolide Angelica sinensis −86.8 −66.2
3,3a,7a,8-tetrahydro-3,6′:7a,7′-diligustilid-8-one Angelica sinensis −80.8 −99.2
estradiol Positive control −92.0 −100.0
zearalenone Positive control −104.1 −104.9
A B
Figure 44 Lowest-energy docked poses of alkaloids [N-trans-feruloyltyramine (aqua), cis-clovamide (red), and trans-clovamide (blue) along
with the co-crystallized ligand, genistein (green)] with ERα (PDB 1X7R). A: Docked poses showing the entire ribbon structure of the protein.
B: Close-up of the docked poses.
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Figure 45 Lowest-energy docked pose of cis-clovamide with ERα (PDB 1X7R) showing the principle amino acid contacts in the binding site.
Hydrogen bonds are indicated by blue dashed lines.
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This molecular docking study has revealed that almost all
popular herbal supplements contain phytochemical compo-
nents that may bind to the human estrogen receptor and
exhibit selective estrogen receptor modulation. As such,
these herbal supplements may cause unwanted side effects
related to estrogenic activity. For example, estrogenic
agents may be effective and potent growth stimulators of
estrogen-receptor positive tumors and pose a hazard toFigure 46 Lowest-energy docked pose of N-trans-feruloyltyramine wi
the binding site. Hydrogen bonds are indicated by blue dashed lines.patients with breast cancer who have ER-positive tumors
and who are being treated with antiestrogens.
The strongest docking (most exothermic docking energies)
phytochemical ligands were phenolic compounds and the
weakest docking ligands were triterpenoids. A common
binding motif for phenolic ligands in ERα is the hydropho-
bic pocket of Leu 387, Phe 404, Met 388, and Leu 391,
along with edge-to-face π–π interactions with Phe 404, and
hydrogen bonds between the phenolic –OH group and theth ERβ (PDB 1X7B) showing the principle amino acid contacts in
Figure 47 Lowest-energy docked pose of the prenylated chalcone kanzonol Y with ERβ (PDB 1X7J) showing the hydrophobic amino
acid contacts with the isoprenyl groups of the ligand.
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356. Similarly, interactions of phenolic ligands with ERβ in-
clude binding in a hydrophobic pocket formed by Leu 298,
Leu 339, and Phe 356; edge-to-face π–π interactions of the
phenolic ligand with Phe 356 and hydrogen boding of the
phenolic –OH group with the carbonyl group of Leu 339,
the guanidine group of Arg 346, and the carboxylate of
Glu 305. Common hydrogen-bonding residues in the bind-
ing sites of ERα are the guanidine group of Arg 394, theA
Figure 48 Lowest-energy docked poses of pregnane steroids [2,3-dihyd
one (dark green), 3,21-dihydroxypregna-5,16-dien-20-one (white), and p
poses showing the entire ribbon structure of the protein. B: Close-up of the dimidazole group of His 524. Hydrogen-bonding residues of
ERβ are Arg 346, His 475.
There are several limitations to these docking results:
 Some of the herbal phytochemicals examined may
not be bioavailable due to limited solubility,
membrane permeability;
 This docking study has only examined docking of
the natural ligands (or their aglycones) and does notB
roxypregn-16-en-20-one (magenta), 3,16-dihydroxypregn-5-en-20-
regnadienolone (bright green)] with ERβ (PDB 1U3R). A: Docked
ocked poses.
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metabolic derivatization;
 The docking studies do not account for synergism in
the estrogen receptor binding;
 The molecular docking method itself suffers from
inherent limitations (e.g., the protein is modeled as a
rigid structure without flexibility, solvation of the
binding site and the ligand is excluded, and free-energy
estimation of protein-ligand complexes is largely
ignored) (Yuriev et al. 2011; Yuriev and Ramsland 2013).
 Docking energies do not provide information about
whether strongly binding ligands may function as
agonists or antagonists of the estrogen receptor.
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